Catalog No.: PC-21147Not For Human Use, Lab Use Only.
Ilorasertib (ABT-348) is a potent inhibitor of Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases (Aur B IC50=2 nM, PDGFRβ IC50=3 nM).
Ilorasertib (ABT-348) is a potent inhibitor of Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases (Aur B IC50=2 nM, PDGFRβ IC50=3 nM). Ilorasertib (ABT-348) inhibits phosphorylation of histone H3, induces of polyploidy, and inhibits proliferation of a variety of leukemia, lymphoma, and solid tumor cell lines (IC(50) = 0.3-21 nM). Ilorasertib (ABT-348) shows potent binding activity (K(i) < 30 nM) against VEGFR/PDGFR families and the Src family of cytoplasmic tyrosine kinases. Ilorasertib (ABT-348) inhibits VEGFR/PDGFR autophosphorylation in cells and inhibition of VEGF-stimulated endothelial cell proliferation (IC(50) ≤ 0.3 nM). Ilorasertib (ABT-348) exhibits antiproliferative activity against BCR-ABL chronic myeloid leukemia cells and cells expressing the gleevec-resistant BCR-ABL T315I mutation. Ilorasertib (ABT-348) demonstrates significant antitumor efficacy in representative solid tumor [HT1080 and pancreatic carcinoma (MiaPaCa), tumor stasis] and hematological malignancy (RS4;11, regression) xenografts.
